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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death globally and in Canada. Diabetes and hypertension
are major risk factors for CVD events. Despite the increasing availability of effective treatments, the majority of diabetic and
hypertensive patients do not have adequate blood pressure and glycemic control. One of the major contributors is poor treatment
adherence.
Objective: This study aims to evaluate the impact of treatment adherence for patients with both diabetes and hypertension on
acute severe CVD events and intermediate clinical outcomes in Canadian primary care settings.
Methods: We will conduct a population-based retrospective cohort study of patients living with both diabetes and hypertension
in Ontario, Canada, between January 1, 2008, and March 31, 2018. The Social Cognitive Theory will be used as a conceptual
framework by which to frame the reciprocal relationship between treatment adherence, personal factors, and environmental
determinants and how this interplay impacts CVD events and clinical outcomes. Data will be derived from the Diabetes Action
Canada National Data Repository. A time-varying Cox proportional hazards model will be used to estimate the impacts of treatment
adherence on CVD morbidity and mortality. Multivariable linear regression models and hierarchical regression models will be
used to estimate the associations between treatment adherence of different medication categories and intermediate clinical
outcomes. Our primary outcome is the association between treatment adherence and the risk of acute severe CVD events, including
CVD mortality. The secondary outcome is the association between treatment adherence and intermediate clinical outcomes
including diastolic and systolic blood pressures, glycated hemoglobin, low-density lipoprotein cholesterol, and total cholesterol.
Owing to data limitation, we use medication prescriptions as a proxy to estimate treatment adherence. We assume that a patient
adhered to medications if she or he had any prescription record in the 4 preceding quarters and 1 quarter after each quarter of
interest. Acute severe CVD events are defined based on the World Health Organization’s Monitoring Trends and Determinants
in Cardiovascular Disease Project, including acute coronary heart disease, stroke, and heart failure. As causes of death are not
available, the number of CVD deaths will be computed using the most recent systolic blood pressure distributions and the
population attributable risks related to systolic blood pressure level.
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Results: The project was funded by Diabetes Action Canada (reference number: 503854) and approved by the University of
Toronto Research Ethics Board (reference number: 36065). The project started in June 2018 and is expected to be finished by
September 2019.
Conclusions: The findings will be helpful in identifying the challenges of treatment adherence for diabetic and hypertensive
patients in primary care settings. This will also help to develop intervention strategies to promote treatment adherence for patients
with multi-morbidities.
International Registered Report Identifier (IRRID): DERR1-10.2196/13571
(JMIR Res Protoc 2019;8(5):e13571)   doi:10.2196/13571
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Introduction
Background
Cardiovascular disease (CVD) is the leading cause of death in
Canada, accounting for one-third of deaths nationally [1].
Diabetes and hypertension are major risk factors for CVDs [2-4].
In 2017, approximately 7.3% and 17.8% of Canadians aged 12
years and older reported being diagnosed with diabetes and
hypertension, respectively [5]. Diabetes and hypertension are
the 2 most common comorbid chronic diseases seen in primary
care consultations. Hypertension is reported in over two-thirds
of patients with type 2 diabetes [6], whereas nearly 50% of
patients with hypertension are diabetic [7]. Despite the
increasing availability of effective treatment regiments and
guidelines, approximately half of the treated patients do not
have adequate blood pressure and glycemic control [8,9]. One
of the major contributors to inadequate control is poor treatment
adherence [9,10]. Treatment adherence is defined as the degree
to which the patient’s behavior corresponds with the agreed
recommendations from a health care provider [11]. Adherence
to antihypertension and antidiabetes medications is proven to
reduce CVD morbidity and mortality, hospitalizations, and
health expenditure [11-17]. Given the potential impacts of
treatment adherence on CVD morbidity and mortality,
quantifying treatment adherence and its impacts will help in the
development of intervention strategies to improve treatment
adherence for patients in primary care settings. This includes
the use of patient-centered approaches such as concordance,
where doctors elicit patients’ views, inform patients of the pros
and cons of taking medicine, and involve patients in treatment
decision making [18]. This type of informed and shared decision
making is believed to improve patient satisfaction, adherence,
and treatment outcomes [19]. Unfortunately, the process of
patient-doctor communication is often not recorded and cannot
be quantified using traditional medical records to understand
adherence behaviors.
Treatment adherence can be measured using either subjective
or objective methods. One of the most frequently used subjective
measures is the Morisky Medication Adherence Scale [20],
which is a patient self-reported tool with 8 items related to
medication-taking behaviors that can be transformed into an
adherence score [21,22]. Morisky scale heavily relies on
patient’s attitudes toward their medications rather than actual
medication-taking behaviors and is vulnerable to significant
recall bias [21,22]. Patients tend to underreport their
nonadherence to avoid disapproval from their physicians or
researchers administering the test [17]. A major limitation of
conducting objective measures of adherence is that
administrative databases often do not record medication taking.
Proxy measures such as prescription refills are used [17] with
the assumption that prescription refill patterns correspond to
medication-taking behavior [23-25]. However, medication refill
patterns can vary substantially across different health care
providers and settings.
Up to now, there were limited studies investigating medication
treatment adherence and its association with CVD events [26-35]
and clinical outcomes [35-40] (Multimedia Appendix 1). Using
refill adherence, previous studies have reported that lower
adherence (<80%) levels were associated with higher risk of
CVD [26], all-cause mortality, and hospitalization for CVD
after adjusting for demographic, socioeconomic status (SES),
and baseline clinical characteristics [29]; higher adherence to
statins (>80%) was associated with significant reduction in
low-density lipoprotein cholesterol (LDL-C) in patients with
diabetes [36]. In these studies, refill adherence was measured
by the medication possession ratio (MPR), reporting the
proportion of days with medications on hand during the
follow-up. In Canada, there have been 12 studies that were
investigated for treatment adherence of patients with diabetes
[41-44], hypertension [30-32,34,45,46], or both [47]
(Multimedia Appendix 1). Of these studies, 5 reported a negative
association between treatment adherence and chronic heart
failure [30,31], end-stage renal disease [31], mortality [32], a
composite of all-cause death and hospitalization for acute
myocardial infarction, heart failure, or stroke [33], and combined
CVD events (coronary artery disease, cerebrovascular disease,
and chronic heart failure) and hospitalization costs [34]. Using
refill adherence, previous studies have showed that lower
treatment adherence (<80%) was associated with higher risk of
coronary disease [36], cerebrovascular disease [36], and chronic
heart failure [36], after adjustment for demographic and SES
[30]. These studies had several common limitations. First, few
studies examined treatment adherence among patients with
multimorbidities, such as both diabetes and hypertension, which
accounted for the majority of these patients and is in line with
studies showing that multimorbidity and medical complexity
increase with age [48]. Second, most studies examined only one
type of medication adherence, not considering the combined
benefits of adhering to multiple medications in preventing CVD
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events and mortality [49,50]. Third, many studies were
cross-sectional in design and relied on survey- or hospital-based
electronic medical records (EMRs) or had a relatively shorter
follow-up time (<10 years), which limited the studies’ ability
to inform clinical practice at the primary care level.
Theoretical Framework
Treatment adherence is largely viewed, and measured, as a
behavior at the individual level [51]. However, adherence is
multifactorial and influenced by a host of environmental
determinants [52-54]. Although often neglected in adherence
studies, environmental determinants have been reported as
barriers to adherence at the individual level [55]. Thus, we intend
to use Social Cognitive Theory as a lens through which to
conceptualize both personal-related factors and environmental
determinants that may influence treatment adherence. Social
Cognitive Theory explains a reciprocal relationship between
that behavior, personal factors, and environmental determinants,
and in the case of health, this interplay impacts health outcomes
(Figure 1) [56,57].
Other studies of adherence at the individual level have employed
the Health Belief Model or Theory of Planned Behavior to
understand how individuals may engage in adherence behavior;
however, these frameworks are limited in application at the
population level and do not adequately explicate environmental
determinants of adherence behaviors [58-60]. Similarly,
theoretical frameworks that include environmental determinants
at the population level, such as the Social-Ecological Model,
while useful in revealing the environmental, organizational, and
social factors influencing health, are limited in ability to
highlight the behavioral mechanisms underpinning adherence
[61]. Thus, the Social Cognitive Theory, which explicitly
includes environmental determinants and personal factors as
contributing to behavior, is well placed to investigate the
population factors that impact adherence.
Our study seeks to examine the ways in which medication
prescription, as proxy for adherence, impacts on CVD events
and clinical outcomes. As shown in our conceptual framework
(Figure 1), the behavior of treatment adherence operates not
only at the individual level but also cumulatively at the
population level. Similarly, health system touchpoints exist and
exert impact at the population level as part of the environmental
determinants of treatment adherence. These factors also interact
with and are influenced by personal factors; however, in our
analysis, we are controlling for these personal-level elements
to highlight the role of medication prescription as an
environmental determinant. We hypothesize that these
environmental factors, measured by primary care provider
characteristics, medication prescription, and medication regimen
complexity over time, in turn, would impact on individual CVD
events and clinical outcomes. Ultimately, this lens allows us to
consider how population-level considerations, such as health
system touchpoints, impact adherence at the population level.
The results will provide evidence that may inform health policy
and specific health service interventions.
Objectives and Hypotheses
Objective 1: The first objective was to assess the impacts of
treatment adherence on acute severe CVD events in Ontario
between January 1, 2008, and March 31, 2018 (10 years).
Hypothesis 1: Patients with a lower adherence rate
of one or more medications (antihypertension,
antidiabetes, statins, and aspirin) are more likely to
develop acute severe CVD events (including death
from CVD), adjusting for potential confounding
factors.
Objective 2: The second objective was to assess the impacts of
treatment adherence on intermediate clinical outcomes in Ontario
between January 1, 2008, and March 31, 2018.
Hypothesis 2: Patients with a higher adherence rate
are associated with significant improvements in
clinical outcomes including diastolic blood pressure,
systolic blood pressure, glycated hemoglobin (HbA1c),
LDL-C, and total cholesterol (TC), adjusting for
potential confounding factors.
Figure 1. Theoretical framework. CVD: cardiovascular disease.
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Study Design and Participants
This is a retrospective cohort study using primary care EMR
data. A cohort of patients who were medically diagnosed with
both diabetes and hypertension between January 1, 2008, and
March 31, 2018, will be included in this study.
Inclusion and Exclusion Criteria for Participants
Time to Enter the Cohort
Cases entered the cohort when a medical diagnosis of both
diabetes and hypertension was present and when a prescription
for any antihypertensives or antidiabetic medication was
provided in the EMR. The exclusion criteria included (1) patients
with a past history of any acute severe CVD event, (2) patients
who developed CVD events during follow-up where no date of
CVD event was present, and (3) patients whose follow-up period
was below 6 quarters as we cannot estimate its treatment
adherence. A total of 15,642 eligible participants are identified
in the finial study population (Figures 2 and 3).
Follow-Up
We will retrospectively follow-up all eligible participants until
March 31, 2018 (by months). Follow-up ends when a participant
dies, has any acute severe CVD event, or by the end of the study
(March 31, 2018). For hypotheses related with clinical outcome,
follow-up ends with the participant’s latest diastolic blood
pressure, systolic blood pressure, HbA1c, LDL-C, and TC
outcomes. The follow-up period will be measured approximately
in months and treated as an independent variable.
Data Source
We will utilize the Diabetes Action Canadian National Diabetes
Repository as the data source. The Repository contains
deidentified data from over 100,000 patients living with diabetes,
currently from 4 Canadian provinces (Ontario, Manitoba,
Quebec, and Alberta). Data are extracted from primary care
EMRs of consenting family physicians and nurse practitioners
by regional Practice Based Research Networks who are members
of the Canadian Primary Care Sentinel Surveillance Network
(CPCSSN) and are managed using previously described
processes developed through CPCSSN [61]. The Repository
provides a Secure Analytic Virtual Environment, which is a
privacy compliant research platform in a high-performance
computing center. Approved researchers access the Secure
Analytic Virtual Environment remotely to analyze datasets
derived from Repository data. All projects are reviewed by the
Repository’s Research Governing Committee, composed of at
least 50% patients, to ensure the project’s values are consistent
with those of patients living with diabetes and of their
caregivers. This project was reviewed and approved by the
Research Governing Committee.
Deidentified patient data from contributing practices in the
Diabetes Repository include the following: (1) patient
demographic characteristics, (2) patient health conditions, (3)
physical and laboratory examinations, (4) medication
prescriptions, (5) risk factors, and (6) comorbidities. A data
dictionary that provides information on data elements is
available at the Diabetes Action Canada website.
Figure 2. Cohort participant selection for the association between treatment adherence and cardiovascular disease (CVD) morbidity and mortality.
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Figure 3. Cohort participant selection for the association between treatment adherence and clinical outcomes. CVD: cardiovascular disease; SBP:systolic
blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin; LDL-C: low-density lipoprotein cholesterol.
Exposure and Study Outcomes
Treatment Adherence Rate
Medication adherence rate is considered the exposure of interest.
Medications will be classified as (1) antidiabetic medications,
including metformin, sulfonylurea, and insulin, inhibitors of
dipeptidyl peptidase 4, meglitinide, sodium-glucose
cotransporter-2 inhibitors, thiazolidinedione, and
alpha-glucosidase enzymes, (2) antihypertensive medications,
including angiotensin converting enzyme inhibitors, thiazide
diuretics, beta-blockers, calcium channel blockers, and
angiotensin II receptor blockers, (3) statins, and (4) aspirin. We
will measure patient adherence to each type of prescription if
prescribed. Theoretically, the adherence rate could be calculated
based on the prescription date and refills. However, we cannot
depend on the refills as this information varies highly among
primary care physicians (eg, some refilled every 3 months,
others provided multiple repeats) [62]. Previous research
indicated that lag-lead approach is feasible to estimate adherence
based on time-dependent associations between different
variables (or the same variable) in longitudinal data analysis
[63]. We will use this approach to account for the variation in
refills. Based on a study using the CPCSSN database, we assume
that patients adhered to medications if they had any prescription
record in the 4 preceding quarters and 1 quarter after each
quarter of interest (lag4, lead1) [64].
Cardiovascular Disease Morbidity and Mortality
The primary outcome is the risk of any acute severe CVD events
including mortality to identify cohort members who developed
acute severe CVD events or who died from acute severe CVD
events during the follow-up. Acute severe CVD events are
defined based on the World Health Organization’s Monitoring
Trends and Determinants in Cardiovascular Disease Project,
including acute coronary heart disease (ICD-9 code 410-412,
414), stroke (ICD-9 code 430-438), and heart failure (ICD-9
code 428) [26,65,66].
We could not access the cause of mortality among patients in
this cohort owing to data limitation. Thus, we estimate the cause
of mortality based on previous research by Bundy et al who
offer a method to estimate the association between systolic blood
pressure and CVD mortality [67]. We will apply this method
to identify cohort members who died from CVD events during
the follow-up. This method assumes that the number of CVD
deaths could be increased if the population developed higher
systolic blood pressure treatment levels. The number of CVD
deaths will be computed using systolic blood pressure
distributions and the population attributable risks (PARs) related
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to systolic blood pressure level. A given PAR represents the
proportion of CVD deaths that could be increased by higher
systolic blood pressure levels. We will divide the most recent
systolic blood pressure level into 8 categories (<130, 130-134,
135-139, 140-144, 145-149, 150-154, 155-159, and ≥160
mmHg). The PARs will be calculated using the formula given
in Figure 4, where pi is the proportion of the systolic blood
pressure category i, HRi is the hazard ratio of CVD deaths in
the systolic blood pressure category i, and k is the total number
of systolic blood pressure categories. To estimate hazard ratios
for CVD mortality comparing each of the 8 systolic blood
pressure categories, Bundy et al conducted a network
meta-analysis of 42 antihypertensive clinical trials [68]. We
will use the hazard ratio of CVD death from the meta-analysis
study conducted by Bundy et al. For patients who died during
the follow-up period, we assume that the patient died from CVD
events if the PAR was higher than 50%.
Clinical Outcomes
The secondary outcomes are the most recent clinical treatment
outcomes, including diastolic blood pressure, systolic blood
pressure, HbA1c, LDL-C, and TC.
Figure 4. Formula for population attributable risks (PARs).
Baseline Covariates and Other Covariates
Based on data availability, we will include the following
personal-related factors: (1) patients’ demographic and
socioeconomic characteristics (ie, sex, age, body mass index,
SES, and rurality), (2) risk factors (ie, smoking history, and
alcohol history), (3) comorbidities and its duration by the end
of the follow-up period (ie, chronic obstructive pulmonary
disease, depression, dementia, and Parkinson), and (4) clinical
outcomes at baseline (ie, diastolic blood pressure, systolic blood
pressure, HbA1c, LDL-C, and TC). Environmental determinants
contributing to treatment adherence include those related to
primary care physicians and health systems: (1) physicians’
demographic characteristics (ie, sex, age, and location type) and
(2) complexity of prescription (ie, the types of medication). All
covariates will be treated as baseline covariates except that we
will measure the incidence of comorbidities and the time to
follow-up.
SES is defined according to the Canadian Material Deprivation
Index [69]. The Canadian Material Deprivation Index, a proxy
for individual-level SES based on the most recent 6-digit
residential postal code, is calculated by the average income,
percentage without high school graduation, and the employment
ratio [70]. SES will be categorized into high, average, and low
SES groups.
Statistical Analysis
The analyses will be described separately for objective 1 and
objective 2. We will include participants with nonmissing
information on treatment adherence. Multiple imputations will
be used to replace missing data for baseline covariates, SES,
and comorbidities. Finally, a practice site will be used as a
random effect in each model. All analyses will be performed in
Stata version 13.0 (Stata Corp LP).
Objective 1
For hypothesis 1, a time-varying Cox proportional hazards
model will be performed to evaluate the hazard ratio between
treatment adherence and the incidence of acute severe CVD and
mortality, adjusting for all potential covariates. In addition, the
interactions of adherence to multiple medications will be
included as a block [71] in the Cox proportional hazards model
to examine the combined benefits of adherence in preventing
CVD events and mortality (model 1). Treatment adherence and
acute severe CVD risk is considered as the exposure of interest
and outcomes, respectively. We will measure follow-up time
(in months) from the date of entry into the cohort until the date
of incident acute severe CVD events, died, or the end of the
follow-up period. Kaplan-Meier survival curves for any acute
severe CVD and mortality by treatment adherence level will be
generated by pooling the survival estimates.
Objective 2
For hypothesis 2, 4 multivariable linear regression models will
be used to test the association between treatment adherence and
the most recent clinical outcomes after adjusting for all potential
covariates (model 2-model 5). An adjusted risk ratio with 95%
CI will be generated. We will build the hierarchical regression
[71] into the linear regression models by including the adherence
to different type of medications as a block to test the aggregated
contribution of adherence to clinical outcomes, including
diastolic blood pressure, systolic blood pressure, HbA1c, LDL-C,
and TC.
Sensitivity Analysis
Previous evidence has also indicated that there is no single
correct lag and lead for estimating time-dependent association
[63]. Lag and lead choices are a significantly important issue
in the generalizability of results [62,72]. Therefore, we will
conduct a sensitivity analysis using lag1 and lead 4 (Multimedia
Appendix 2). Additionally, we will examine the consistency of
the results regarding the following: (1) at different treatment
adherence categories (ie, ≥80%, 60% to 80%, 40% to 60%, and
≤40%) and (2) with and without multiple imputation of missing
data on all covariates.
Ethics Approval
The study was approved by the University of Toronto Research
Ethics Board (reference number: 36065). Data were deidentified
when analyzed.
Results
The project was funded in July 2017 under Diabetes Action
Canada (reference number: 503854). The study was approved
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by the University of Toronto Research Ethics Board (reference
number: 36065). The project was started in June 2018. The
results are expected to be finished by September 2019.
Discussion
Strengths
CVD events represent a heavy disease burden on individuals
and their families, the health system, and society in general.
Improving treatment adherence to antihypertensive and
antidiabetic medication has been well documented as an
effective strategy to prevent CVD events. Compared with
previous research, our study has several strengths. First, we will
contribute new knowledge on the association between treatment
adherence, acute CVD events, and clinical outcomes among
patients with both diabetes and hypertension in the primary care
setting. Second, we will examine the combined benefits of
adhering to multiple medications in preventing CVD events and
mortality and clinical treatment outcomes. Finally, our study
provides further knowledge by addressing the limitations of
previous studies, such as inclusion of important potential
confounders such as comorbidities, their duration, and follow-up.
For example, previous research reported that mental health
conditions (ie, depression, anxiety, and dementia) were
important factors when analyzing treatment adherence and CVD
events but lacked the ability to identify such mental conditions
[73,74]. Many studies have used the Charlson Comorbidity
Index [27-29] to explore the combined effects of comorbidities
(ie, chronic obstructive pulmonary disease, depression, chronic
kidney disease, and dementia), but this approach does not reflect
the role of individual comorbidities. Furthermore, these studies
did not control for duration of comorbidities. Finally, baseline
clinical characteristics such as HbA1c, lipids, blood pressure,
and body mass index are also important confounding factors,
which may have a direct impact on CVD risk and clinical
treatment outcomes [75]. However, few studies control for these
factors. We will address the limitations by controlling body
mass index, diastolic blood pressure, systolic blood pressure,
HbA1c, LDL-C, and TC. Owing to the data availability, the
percentage of missing data at baseline is as follows: body mass
index (25.25%), diastolic blood pressure (23.54%), systolic
blood pressure (18.27%), HbA1c (28.09%), LDL-C (46.21%),
and TC (45.92%). We will use multiple imputation and
consequently carry out a sensitivity analysis with and without
imputation of missing data on all covariates. Our study will be
the first population-based cohort study that systematically
investigates the impacts of treatment adherence for patients with
both diabetes and hypertension on CVD morbidity and mortality,
and clinical treatment outcomes using a longitudinal and
large-scale primary care EMR data. Our findings will help to
identify challenges in treatment adherence for patients with
diabetes and hypertension in primary care settings. Through
this study, we hope to provide valuable evidence for policy and
practice to inform the design and implementation of primary
care health services to support adherence among patients living
with diabetes and hypertension.
Limitations
Several limitations should be noted in our study. First, this study
is a retrospective study. All data were recorded from routine
EMRs with possible errors and omissions. Thus, CVD may not
be captured in full. As recording the medical diagnosis of
diabetes, hypertension, and CVD is the responsibility of primary
care physicians, there may be delays in EMR input. Second,
treatment adherence is measured using a proxy, not a real
measure. Theoretically, patients with both diabetes and
hypertension are regarded as having a high risk of CVD events
and should take prescribed medications consistently. We assume
that prescription patterns correspond to medication-taking
behavior. Third, owing to data limitations, we estimate CVD
mortality using systolic blood pressure distributions and the
population attributable risks related to the systolic blood pressure
level. Fourth, aspirin is an over-the-counter medication that
patients can obtain from pharmacies without a prescription.
Thus, we may underestimate the adherence rates for aspirin.
Finally, we employed the Social Cognitive Theory to explore
the reciprocal relationship between that treatment adherence
and diabetes/hypertension management outcomes (such as
CVD), in the context of personal factors and environmental
determinants. However, there were many factors not recorded
in our database. For example, there were no variables such as
primary language, ethnicity, health literacy, employment status,
and marital status, which are factors contributing to patient
understanding of the treatment or related to their daily
management. There were no process variables recorded such
as patient’s level of involvement in the treatment
decision-making process, understanding of their disease, and
family and social support. In addition, there was a lack of
reporting on physician-specific variables, such as the level of
communication to patients on the benefits and adverse effects
of a prescription nor did we have variables related to the health
system such as access to primary care and primary care models
[15]. These limitations may lead to potential bias.
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